TBBCF awards 4 new research grants By KATHEEN EDGECOMB The Terri Brodeur Breast Cancer Foundation has awarded $400,000 in grants to four researchers who are looking for a cure for breast cancer and better ways to treat the disease in those already diagnosed. The foundation’s scientific advisory board chaired by founding member Nicholas Saccomano, PhD, […]
TBBCF awards 4 new research grants Read More »
Big Y donates $3,772 through their Partners of Hope and reusable shopping bag campaigns By ELLEN SWERCEWSKI Big Y has donated $3,000 to the Terri Brodeur Breast Cancer Foundation as part of its annual Partners of Hope Campaign, and another $772 for the Big Y reusable shopping bag campaign. On Feb. 14, 2020, Big Y
Big Y donates $3,772 to TBBCF Read More »
Jennifer L. Guerriero, PhD Dana-Farber Cancer Institute – Harvard Medical School Modulating the immune system as an anti-cancer strategy has shown great promise in some types of cancer, however there has been limited responses in breast cancer. While the main focus of immunotherapy has been on the adaptive immune system, namely T cells, harnessing innate
Jennifer L. Guerriero, PhD Read More »
Sheheryar K. Kabraji, BM BCh Dana-Farber Cancer Institute – Harvard Medical School While effective HER2-targeting drugs have greatly improved outcomes for patients with HER2-positive (HER2+) breast cancer, relapse and recurrence still occur. When HER2+ breast cancer returns after treatment, it is because some cancer cells survive killing, and are known as minimal residual disease (MRD). To
Sheheryar K. Kabraji, BM BCh Read More »
Naiara Perurena, PhD, PharmD Brigham and Women’s Hospital – Harvard Medical School Around 15-20% of breast cancers are characterized by the amplification or overexpression of the receptor tyrosine kinase HER2 and are therefore classified as HER2-positive. In these tumors, HER2 drives tumor formation and progression by activating an oncogenic signaling cascade. Fortunately, the development of
Naiara Perurena, PhD Read More »
Jan Remsik, PhD, PharmD Memorial Sloan Kettering Cancer Center Leptomeningeal metastasis (LM), or the spread of tumor cells into the cerebrospinal fluid, is an increasingly common complication of cancer that results in rapid neurologic disability and death. Colonization of leptomeningeal space by cancer cells can take years or even decades after primary cancer diagnosis. The
Jan Remsik, PhD PharmD Read More »
